Abstract
Diabetic Kidney Disease (DKD) is one of the major complications of Diabetes Mellitus (DM) and is currently the most common cause of End-Stage Renal Disease (ESRD) worldwide. Traditionally, DKD is considered a disease which has nothing to do with the immune system, and the pathogenesis is mainly characterized to be metabolic disturbance. Recent growing evidence indicates immunologic and inflammatory mechanisms in the development and progression of DKD. This overview of macrophages, dendritic cells, T lymphocytes, B lymphocytes, neutrophils and mast cells is closely involved in the pathologic process of DKD, with more emphasis on the leucocyte accumulation and related molecular mechanisms. Moreover, the potential contributions of these immune cells to renal injury will also be discussed. Specifically, these findings help to identify new potential therapeutic targets of DKD. Future preclinical and clinical studies might translate these exciting findings into clinical applications.
Keywords: Diabetic kidney disease, Immune cells, Pathogenesis, Therapeutic methods, End stage renal disease, Diabetes mellitus.
Current Gene Therapy
Title:Role of Immune Cells in Diabetic Kidney Disease
Volume: 17 Issue: 6
Author(s): Xiaoqian Yang and Shan Mou*
Affiliation:
- Department of Nephrology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, 160 Pujian Road, Shanghai 200127,China
Keywords: Diabetic kidney disease, Immune cells, Pathogenesis, Therapeutic methods, End stage renal disease, Diabetes mellitus.
Abstract: Diabetic Kidney Disease (DKD) is one of the major complications of Diabetes Mellitus (DM) and is currently the most common cause of End-Stage Renal Disease (ESRD) worldwide. Traditionally, DKD is considered a disease which has nothing to do with the immune system, and the pathogenesis is mainly characterized to be metabolic disturbance. Recent growing evidence indicates immunologic and inflammatory mechanisms in the development and progression of DKD. This overview of macrophages, dendritic cells, T lymphocytes, B lymphocytes, neutrophils and mast cells is closely involved in the pathologic process of DKD, with more emphasis on the leucocyte accumulation and related molecular mechanisms. Moreover, the potential contributions of these immune cells to renal injury will also be discussed. Specifically, these findings help to identify new potential therapeutic targets of DKD. Future preclinical and clinical studies might translate these exciting findings into clinical applications.
Export Options
About this article
Cite this article as:
Yang Xiaoqian and Mou Shan *, Role of Immune Cells in Diabetic Kidney Disease, Current Gene Therapy 2017; 17 (6) . https://dx.doi.org/10.2174/1566523218666180214100351
DOI https://dx.doi.org/10.2174/1566523218666180214100351 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Influence of Glycation of Plasma Proteins in Diabetes on the Binding Interaction with Polyphenols
Current Drug Metabolism A Facile and Economical Method to Synthesize Vildagliptin
Letters in Organic Chemistry Editorial [ Endothelial Dysfunction: Novel Therapeutic Approaches (Guest Editor: Dimitris Tousoulis)]
Current Vascular Pharmacology Exploring Natural Products as a Source for Antidiabetic Lead Compounds and Possible Lead Optimization
Current Topics in Medicinal Chemistry (Pro)renin Receptor as a New Drug Target
Current Pharmaceutical Design Steatohepatitis in HIV-Infected Subjects: Pathogenesis, Clinical Impact and Implications in Clinical Management
Current HIV Research A Diabetes Treatment Strategy to Reduce the Risk of Cardiovascular Events: Clinical Benefits and Potential of Linagliptin
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) 3D Printing Technology Over a Drug Delivery for Tissue Engineering
Current Pharmaceutical Design Advanced Glycation End Products (AGEs), Oxidative Stress and Diabetic Retinopathy
Current Pharmaceutical Biotechnology Inflammation in Ischemic Stroke Subtypes
Current Pharmaceutical Design Virtual Screening Based Discovery of PTP1B Inhibitors and Their Biological Evaluations
Letters in Drug Design & Discovery Current Therapy in Sarcoidosis, the Role of Existing Drugs and Future Medicine
Inflammation & Allergy - Drug Targets (Discontinued) Hidden Hunger of Vitamin E among Healthy College Students: A Cross- Sectional Study
Endocrine, Metabolic & Immune Disorders - Drug Targets The Wnt/β-catenin Signalling Pathway Inhibitor Sclerostin is a Biomarker for Early Atherosclerosis in Obesity
Current Neurovascular Research Adverse Drug Reactions Amongst Adult Patients Admitted in Lagos State University Teaching Hospital Lagos, Nigeria
Current Drug Safety Mitochondrial Aldehyde Dehydrogenase, A Potential Drug Target for Protection of Heart and Brain from Ischemia/Reperfusion Injury
Current Drug Targets Dyslipidemia and Cardiovascular Disease Prevention in South Asians: A Review and Discussion of Causes, Challenges and Management Strategies
Current Diabetes Reviews 24-Hour Blood Pressure Control – A Predictor for Clinical Outcomes
Current Hypertension Reviews CSII as an Alternative Therapeutic Strategy for Managing Type 2 Diabetes: Adding the Indian Experience to a Global Perspective
Current Diabetes Reviews Preface
Current Pharmaceutical Design